Credit Rating

Rating UpgradedCredit & Debt View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹350.00

prior close

₹358.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-0.5% vs market

Pharmaceuticals peers, median of 150sector-0.1%+0.2% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-1.1

15m

-0.3

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.5-0.5-0.1+0.2

Next day

+0.6+1.0-0.5-0.0+0.6

+0.0+1.0-0.9-0.0+0.1

-0.9+2.4-3.2+0.4-1.3

-0.6+3.1-3.7+1.3-1.9

-0.8+3.6-4.4+1.8-2.6

-1.4+1.7-3.1+1.3-2.7

15d

-2.3+1.8-4.1-0.9-1.4

+1.0+3.6-2.6+1.4-0.4

-0.9+1.0-1.9+0.0-0.9

-9.2+0.5-9.7-2.5-6.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Crisil has upgraded Samrat Pharmachem's credit ratings on its bank facilities worth Rs.30 crore (Cash Credit of Rs.28 crore and Forex Forward of Rs.2 crore from ICICI Bank). The long-term rating moved up from BB+/Stable to BBB-/Stable, and the short-term rating improved from A4+ to A3. The upgrade reflects improved business risk profile, with revenue of Rs.214 crore in 9M FY2025 and operating margin recovering to about 4.7% (Q3 FY2025 saw ~6.5%). The company has a strong capital structure with low debt (gearing of 0.13x and networth of Rs.64.99 crore as of March 2024). Samrat Pharmachem is a 30-year-old iodine derivatives manufacturer based in Ankleshwar, Gujarat, serving pharmaceuticals, FMCG, animal feed and agrochemical sectors.

Likely market impact

Positive for shareholders — the upgrade signals improving financial health and lower borrowing costs going forward. Both ratings have moved closer to investment grade, reflecting Crisil's confidence in the company's earnings recovery and debt-free balance sheet.